One such therapy that revolutionized the treatment of pediatric ALL is blinatumomab, a bispecific T-cell engager, consisting of two fragments: one that binds CD19 on B cells and another that binds CD3 and activates T cells. Here, CD19 is linked to acute lymphoblastic leukemia.